16 December 2025
"In light of the Egyptian Drug Authority's (EDA) commitment to continuously keeping pace with modern scientific developments to ensure the availability of advanced high-tech products while guaranteeing their quality, safety, and efficacy;
The Egyptian Drug Authority – Central Administration for Biological and Innovative Products and Clinical Trials – announces the publication of the following draft regulatory guideline:
Guideline for Good Regulatory Oversight of Clinical Trials by Egyptian Drug Authority
We are honored to receive your feedback via the "Public Consultation Form" at the following email address: ct.scts@edaegypt.gov.eg
The consultation period is open from December 16, 2025, to December 30, 2025.
To review the draft guideline, please click here."